How Clonal Hematopoiesis Affects People Treated With Chemotherapy and Radiation for Solid Cancers
Studies how clonal hematopoiesis relates to outcomes in adults treated for solid cancers.
Key facts
- Who runs it
- Dana-Farber Cancer Institute
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 4 Apr 2025
- Expected to end
- 31 Mar 2035
- Type of study
- Observational, 3 groups
- Treatments tested
- Samples
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid cancer who are about to start chemotherapy or radiation for the first time. It studies blood changes called clonal hematopoiesis.
- Age
- Adults over 18 years
- Sex
- All sexes
- Disease stage
- Solid cancer: breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma.
- Earlier treatment
- Must not have had chemotherapy or radiation before for this solid cancer. Must have a plan to receive chemotherapy or radiation.
Main reasons for not taking part
- No plan for chemotherapy, radiation or PARP inhibitor treatment
- Chemotherapy or radiation already received for the current solid cancer
- Any past blood cancer, such as leukemia, myelodysplastic syndrome, lymphoma or multiple myeloma
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Participants to be included in this study include the following:
- Adults age >18 years
- Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)
- Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer)
- Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past
Who cannot take part
- Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure
- Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)
- Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesContact: Cindy Amaya Lopez, BATaking people
About the trial
What the trial wants to find out
The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.
Read full original descriptionShow less
The study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).
Ultimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.
The 3 groups in the trial
- HEREDITARY RISK
Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit or at patient's home via remote collection. Participants will be asked to donate any the following tissue types: - Blood - Buccal swab (saliva) or mouthwash.
Treatment: Samples
- EXPOSED HIGH RISK
Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit or at patient's home via remote collection. Participants will be asked to donate any the following tissue types: - Blood - Buccal swab (saliva) or mouthwash.
Treatment: Samples
- PRECURSOR LESIONS
Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit or at patient's home via remote collection. Participants will be asked to donate any the following tissue types: - Blood - Buccal swab (saliva) or mouthwash.
Treatment: Samples
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Plain-language title
- How Clonal Hematopoiesis Affects People Treated With Chemotherapy and Radiation for Solid CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 30 June 2026